1.Solution pH jump during antibody and Fc-fusion protein thaw leads to increased aggregation
Kent P. KEVIN ; Schroeder E. CHAD ; Sharma CHANDANA
Journal of Pharmaceutical Analysis 2018;8(5):302-306
Freeze-thaw cycles impact the amount of aggregation observed in antibodies and Fc-fusion proteins. Various formulation strategies are used to mitigate the amount of aggregation that occurs upon putting a protein solution through a freeze-thaw cycle. Additionally, low pH solutions cause native antibodies to unfold, which are prone to aggregate upon pH neutralization. There is great interest in the mechanism that causes therapeutic proteins to aggregate since aggregate species can cause unwanted im-munogenicity in patients. Herein, an increase in aggregation is reported when the pH is adjusted from pH 3 up to a pH ranging from pH 4 to pH 7 during the thaw process of a frozen antibody solution. Raising the pH during the thaw process caused a significant increase in the percent aggregation observed. Two antibodies and one Fc-fusion protein were evaluated during the pH jump thaw process and similar ef-fects were observed. The results provide a new tool to study the kinetics of therapeutic protein ag-gregation upon pH increase.
2.Chemotherapy induced liver abnormalities: an imaging perspective.
Ankush SHARMA ; Roozbeh HOUSHYAR ; Priya BHOSALE ; Joon Il CHOI ; Rajesh GULATI ; Chandana LALL
Clinical and Molecular Hepatology 2014;20(3):317-326
Treating patients undergoing chemotherapy who display findings of liver toxicity, requires a solid understanding of these medications. It is important for any clinician to have an index of suspicion for liver toxicity and be able to recognize it, even on imaging. Cancer chemotherapy has evolved, and newer medications that target cell biology have a different pattern of liver toxicity and may differ from the more traditional cytotoxic agents. There are several hepatic conditions that can result and keen clinical as well as radiographic recognition are paramount. Conditions such as sinusoidal obstructive syndrome, steatosis, and pseudocirrhosis are more commonly associated with chemotherapy. These conditions can display clinical signs of acute hepatitis, liver cirrhosis, and even liver failure. It is important to anticipate and recognize these adverse reactions and thus appropriate clinical action can be taken. Often times, patients with these liver manifestations can be managed with supportive therapies, and liver toxicity may resolve after discontinuation of chemotherapy.
Adult
;
Aged
;
Antibiotics, Antineoplastic/adverse effects/therapeutic use
;
Antimetabolites, Antineoplastic/adverse effects/therapeutic use
;
Antineoplastic Agents/*adverse effects/therapeutic use
;
Antineoplastic Agents, Alkylating/adverse effects/therapeutic use
;
Drug-Induced Liver Injury/etiology/radiography
;
Enzyme Inhibitors/adverse effects/therapeutic use
;
Fatty Liver/etiology/radiography
;
Female
;
Humans
;
Immunotherapy
;
Liver Cirrhosis/etiology/radiography
;
Liver Diseases/etiology/*radiography
;
Male
;
Middle Aged
;
Neoplasms/therapy
;
Tomography, X-Ray Computed